Edouard-Jules Laforgue ggfggfff t

Publications

Article dans une revue (46)

SONOPS Multicentre Cross-Sectional Study Mélanie Duval,Maud Rodney,Morgane Rousselet,Choosie Jaquin,Elsa Garotet al. International Dental Journal, 2025, ⟨10.1016/j.identj.2025.02.007⟩ Article dans une revue hal-04955700v1
ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder Abd El Kader Ait Tayeb,Edouard‐jules Laforgue,Benoit Schreck,Marie Grall‐bronnec,Jean‐benoit Hardouinet al. Fundamental & Clinical Pharmacology, 2025, 39 (3), pp.e70013. ⟨10.1111/fcp.70013⟩ Article dans une revue hal-05099112v1
Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance database Louis Asselin,Edouard-Jules Laforgue,Mélanie Duval,Bruno Revol,Gwenaëlle Veyracet al. Therapies, 2025, S0040-5957 (25), pp.00104-0. ⟨10.1016/j.therap.2025.07.002⟩ Article dans une revue hal-05392660v1
Delphi Consensus Among French Obesity Experts on Clinical Recommendations for Drug Prescription in Patients With Severe Obesity Sarah Berdot,Germain Perrin,Emmanuel Disse,Armelle Arnoux,Eric Bertinet al. Obesity Reviews, 2025, 26 (12), pp.e13977. ⟨10.1111/obr.13977⟩ Article dans une revue hal-05228358v1
Thromboembolic complications following recreational use of nitrous oxide: A French Addictovigilance alert Caroline Victorri-Vigneau,Marylène Guerlais,Emmanuelle Jaulin,Edouard-Jules Laforgue,Marc-Antoine Pistorius Thrombosis Research, 2024, 241, pp.109096. ⟨10.1016/j.thromres.2024.109096⟩ Article dans une revue hal-04785734v1
“Naloxone? Not for me!” First cross-assessment by patients and healthcare professionals of the risk of opioid overdose Aurélie Aquizerate,Morgane Rousselet,Axel Cochard,Marylène Guerlais,Marie Gerardinet al. Harm Reduction Journal, 2024, 21 (1), pp.20. ⟨10.1186/s12954-024-00941-y⟩ Article dans une revue hal-04765025v1
ADHD: prevalence and effect on opioid use disorder treatment outcome in a French sample of patients receiving medication for opioid use disorder—the influence of impulsivity as a mediating factor Auxane Beslot,Marie Grall-Bronnec,Marianne Balem,Benoît Schreck,Edouard-Jules Laforgueet al. Harm Reduction Journal, 2024, 21 (1), pp.165. ⟨10.1186/s12954-024-01079-7⟩ Article dans une revue hal-04717296v1
ESCAPE study: Cannabidiol use in patients treated for substance use disorders, prevalence of use and characteristics of users. Mélanie Duval,Marion Istvan,Morgane Rousselet,Edouard-Jules Laforgue,Marie Grall-Bronnecet al. European Addiction Research, 2024, pp.1-20. ⟨10.1159/000541887⟩ Article dans une revue hal-04824065v1
A revisited version of the disputatio for pharmacological training: An educational study Louise Carton,Perle Totoson,Edouard-Jules Laforgue,Jean-Marc Pelerin,Thomas Portier-Feunteunet al. Therapies, 2024, 79 (4), pp.435-441. ⟨10.1016/j.therap.2023.10.016⟩ Article dans une revue hal-04805817v1
Are the self-stigma and perceived stigma of patients treated with methadone or buprenorphine still a problem fifty years after the marketing authorization for opioid agonist treatment? The observational STIGMA study Mélanie Pinhal,Benoît Schreck,Juliette Leboucher,Caroline Victorri-Vigneau,Edouard-Jules Laforgueet al. Addiction Science and Clinical Practice, 2024, 19, pp.74. ⟨10.1186/s13722-024-00506-1⟩ Article dans une revue hal-04994166v1
Cannabinoid Hyperemesis Syndrome Presumed Secondary to CBD Use: A Case Report Emilie Lefebvre,Luc Simons,Mélanie Duval,Edouard Laforgue,Caroline Victorri-Vigneau Journal of Addiction Medicine, 2024, ⟨10.1097/ADM.0000000000001378⟩ Article dans une revue hal-04792448v1
Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database Julien Li,Yoann Zelmat,Wilhelm Storck,Edouard Laforgue,Antoine Yrondiet al. Journal of Affective Disorders, 2024, 350, pp.452-467. ⟨10.1016/j.jad.2024.01.119⟩ Article dans une revue hal-04789390v1
Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study Mélanie Duval,Aurélie Aquizerate,Emmanuelle Jaulin,Morgane Rousselet,Emmanuelle Kuhnet al. Therapies, 2024, ⟨10.1016/j.therap.2024.07.001⟩ Article dans une revue hal-04765493v1
Evolution of the profiles of new psychotropic drug users before and during the COVID-19 crisis: an original longitudinal approach through multichannel sequence analysis using the French health-care database Marion Istvan,Mélanie Duval,Karl Hodel,Aurélie Aquizerate,Anicet Chaslerieet al. European Archives of Psychiatry and Clinical Neuroscience, 2024, ⟨10.1007/s00406-024-01774-3⟩ Article dans une revue hal-04792516v1
Characterization of antipsychotic utilization before clozapine initiation for individuals with schizophrenia: an innovative visualization of trajectories using French National Health Insurance data Edouard-Jules Laforgue,Marion Istvan,Anicet Chaslerie,Pascal Artarit,Geneviève Vallotet al. Epidemiology and Psychiatric Sciences, 2023, 32, pp.e59. ⟨10.1017/S2045796023000732⟩ Article dans une revue inserm-04215734v1
New Psychoactive Substances, New Behaviours, New Drug-drug Interactions: Pharmacology of a Slam Session Benoît Schreck,Marion Istvan,Marylène Guerlais,Edouard-Jules Laforgue,Marie Gérardinet al. Current Drug Metabolism, 2023, 24 (2), pp.80-91. ⟨10.2174/1389200224666230228103922⟩ Article dans une revue istex hal-04795180v1
Nitrous oxide: a unique official French addictovigilance national survey Marylène Guerlais,Aurélie Aquizerate,Arthur Lionnet,Amélie Daveluy,Mélanie Duvalet al. Frontiers in Public Health, 2023, 11, pp.1167746. ⟨10.3389/fpubh.2023.1167746⟩ Article dans une revue hal-04765021v1
Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study Aurélie Aquizerate,Edouard-Jules Laforgue,Marion Istvan,Morgane Rousselet,Marie Gérardinet al. International Journal of Mental Health and Addiction, 2023, ⟨10.1007/s11469-023-01078-y⟩ Article dans une revue hal-04795227v1
French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change Aurélie Aquizerate,Edouard-Jules Laforgue,Marion Istvan,Morgane Rousselet,Marie Gerardinet al. European Journal of Public Health, 2023, 33 (2), pp.169-175. ⟨10.1093/eurpub/ckad003⟩ Article dans une revue hal-04765007v1
Nitrous oxide in France: Evolution of complications reported to the French monitoring system in the context of information from health authorities and regulatory measures Marylène Guerlais,Aurélie Aquizerate,Amélie Daveluy,Arthur Lionnet,Marie Gerardinet al. International Journal of Drug Policy, 2023, pp.104172. ⟨10.1016/j.drugpo.2023.104172⟩ Article dans une revue hal-04794897v1
Efficacy and Safety of Electroconvulsive Therapy in Patients With Deep Brain Stimulation Nicolas Bukowski,Andrew Laurin,Edouard Laforgue,Cécile Preterre,Tiphaine Rouaudet al. Journal of ECT, 2022, 38 (3), pp.e29-e40. ⟨10.1097/YCT.0000000000000828⟩ Article dans une revue hal-04783913v1
Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior Marion Istvan,Benoît Schreck,Marie Mainguy,Pascale Jolliet,Marie Grall-Bronnecet al. Journal of Clinical Medicine, 2022, 11 (8), pp.2176. ⟨10.3390/jcm11082176⟩ Article dans une revue hal-03678956v1
Evolution of sexual functioning of men through treated and untreated depression É-J Laforgue,G. Busnel,D. Lauzeille,M. Bronnec,Clémence Cabelguenet al. L'Encéphale, 2022, 48 (4), pp.383-389. ⟨10.1016/j.encep.2021.06.008⟩ Article dans une revue hal-03406872v1
Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users Edouard-Jules Laforgue,Morgane Rousselet,Antoine Claudon,Aurélie Aquizerate,Pascale Jollietet al. International Journal of Environmental Research and Public Health, 2022, 19 (15), pp.8920. ⟨10.3390/ijerph19158920⟩ Article dans une revue hal-04764984v1
How do people who use drugs receiving Opioid Medication Therapy perceive their treatment ? A multicentre study Morgane Guillou Landreat,Antoine Dany,Gaëlle Challet-Bouju,Edouard-Jules Laforgue,Jennifer Choletet al. Harm Reduction Journal, 2022, 19 (1), pp.31. ⟨10.1186/s12954-022-00608-6⟩ Article dans une revue hal-03629554v1
Did the pattern of use of zolpidem change since the enforcement of a new prescription rule? A latent class analysis using the French health insurance database Marion Istvan,Morgane Rousselet,Edouard-Jules Laforgue,Marylène Guerlais,Marie Gérardinet al. Expert Opinion on Drug Safety, 2022, 21 (9), pp.1225-1234. ⟨10.1080/14740338.2022.2047930⟩ Article dans une revue hal-04796549v1
A prospective multicenter assessor-blinded randomized controlled study to compare the efficacy of short versus long protocols of electroconvulsive therapy as an augmentation strategy to clozapine in patients with ultra-resistant schizophrenia (SURECT study) Virginie Moulier,Mohamed Wassim Krir,Marine Dalmont,Olivier Guillin,Maud Rothärmelet al. Trials, 2021, 2021 (22), pp.284. ⟨10.1186/s13063-021-05227-3⟩ Article dans une revue hal-05322770v1
Slam Practice : Benoît Schreck,Caroline Victorri-Vigneau,Marylène Guerlais,Edouard-Jules Laforgue,Marie Grall-Bronnec European Addiction Research, 2021, 27 (3), pp.161-178. ⟨10.1159/000511897⟩ Article dans une revue hal-04994156v1
CYP1A2 and tobacco interaction Malcolm Barrangou-Poueys-Darlas,Marylène Guerlais,Edouard-Jules Laforgue,Ronan Bellouard,Marion Istvanet al. Drug Metabolism Reviews, 2021, 53 (1), pp.30-44. ⟨10.1080/03602532.2020.1859528⟩ Article dans une revue hal-03407082v1
ZORRO: When the mask falls off—Comment Marion Istvan,Edouard-Jules Laforgue,Marylène Guerlais,Pascale Jolliet,Caroline Victorri-Vigneau British Journal of Clinical Pharmacology, 2021, ⟨10.1111/bcp.15086⟩ Article dans une revue hal-03406898v1
What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database Edouard-Jules Laforgue,Marion Istvan,Marylène Guerlais,Anicet Chaslerie,Pascal Artaritet al. Expert Opinion on Drug Safety, 2021, 20 (10), pp.1247-1256. ⟨10.1080/14740338.2021.1939304⟩ Article dans une revue hal-03406940v1
Regulatory Framework Implementation for the Prescription of Zolpidem in France, What Impact in the Older People? Alexandra Jobert,Marion Istvan,Edouard-Jules Laforgue,Benoît Schreck,Caroline Victorri-Vigneau International Journal of Environmental Research and Public Health, 2021, 18, ⟨10.3390/ijerph182212099⟩ Article dans une revue hal-03445931v1
Change in the regulatory framework for zolpidem Marion Istvan,Pascal Caillet,Morgane Rousselet,Marylène Guerlais,Edouard-Jules Laforgueet al. British Journal of Clinical Pharmacology, 2021, 87 (8), pp.3310-3319. ⟨10.1111/bcp.14753⟩ Article dans une revue hal-03407064v1
Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Alexandra Jobert,Edouard Laforgue,Marie Grall-Bronnec,Morgane Rousselet,Morgane Péréet al. European Journal of Clinical Pharmacology, 2021, 77 (2), pp.171-177. ⟨10.1007/s00228-020-03007-7⟩ Article dans une revue hal-03244134v1
What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report Morgane Guillou-Landréat,Antoine Dany,Gaëlle Challet-Bouju,Edouard Laforgue,Juliette Leboucheret al. International Journal of Environmental Research and Public Health, 2021, 18 (4), pp.1425. ⟨10.3390/ijerph18041425⟩ Article dans une revue hal-03211107v1
Are Seniors Dependent on Benzodiazepines? Caroline Victorri-Vigneau,Edouard-Jules Laforgue,Marie Grall-Bronnec,Morgane Guillou-Landreat,Morgane Rousseletet al. Clinical Pharmacology and Therapeutics, 2021, 109 (2), pp.528-535. ⟨10.1002/cpt.2025⟩ Article dans une revue hal-03407111v1
Cannabinoid Hyperemesis Syndrome Among Pregnant Women Edouard-Jules Laforgue,Aurore Lesage,Benoît Schreck,Marylène Guerlais,Caroline Victorri-Vigneau Journal of Studies on Alcohol and Drugs, 2020, 81 (6), pp.824-825. ⟨10.15288/jsad.2020.81.824⟩ Article dans une revue hal-03407086v1
Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A/G Polymorphism on Its Effectiveness Audrey Verholleman,Caroline Victorri-Vigneau,Edouard Laforgue,Pascal Derkinderen,Celine Verstuyftet al. International Journal of Molecular Sciences, 2020, 21 (8), pp.3002. ⟨10.3390/ijms21083002⟩ Article dans une revue hal-03159491v1
Cathinone Use Disorder in the Context of Slam Practice Benoît Schreck,Marylène Guerlais,Edouard Laforgue,Célia Bichon,Marie Grall-Bronnecet al. Frontiers in Psychiatry, 2020, 11, ⟨10.3389/fpsyt.2020.00705⟩ Article dans une revue hal-04063101v1
Do Older People Know Why They Take Benzodiazepines? A National French Cross-Sectional Survey of Long-Term Consumers Edouard‐jules Laforgue,Alexandra Jobert,Morgane Rousselet,Marie Grall-Bronnec,Pascale Jollietet al. International Journal of Geriatric Psychiatry, 2020, 35 (8), pp.870-876. ⟨10.1002/gps.5307⟩ Article dans une revue hal-03159473v1
Relevance of CYP2B6 and CYP2D6 Genotypes to Methadone Pharmacokinetics and Response in the OPAL Study Caroline Victorri-Vigneau,Céline Verstuyft,Régis Bouquié,Edouard Laforgue,Jean-Benoit Hardouinet al. British Journal of Clinical Pharmacology, 2019, 85 (7), pp.1538-1543. ⟨10.1111/bcp.13936⟩ Article dans une revue hal-03158829v1
Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients With Long-Term Opioid Substitution Therapy: The OPAL Study Marie Grall-Bronnec,Edouard Laforgue,Gaëlle Challet-Bouju,Jennyfer Cholet,Jean-Benoit Hardouinet al. Frontiers in Psychiatry, 2019, 10, pp.726. ⟨10.3389/fpsyt.2019.00726⟩ Article dans une revue hal-03158795v1
Management of Emergency Electroconvulsive Therapy in the Intensive Care Unit for Life-Threatening Psychiatric Conditions: A Case Series Samuel Bulteau,Edouard Laforgue,Loïc Chimot,Romain Dumont,Olivier Loutrelet al. The journal of ECT, 2018, 34 (1), pp.55-59. ⟨10.1097/YCT.0000000000000451⟩ Article dans une revue hal-03158600v1
Bipolar Disorder and Adherence: Implications of Manic Subjective Experience on Treatment Disruption Samuel Bulteau,Marie Grall-Bronnec,Pierre-Yves Bars,Edouard Laforgue,François Etcheverrigarayet al. Patient Preference and Adherence, 2018, 12, pp.1355-1361. ⟨10.2147/PPA.S151838⟩ Article dans une revue hal-03158599v1
Dynamics of Postural Control during Repetitive Transcranial Magnetic Stimulation in an Adult with Major Depressive Disorder Thibault Deschamps,Anne Sauvaget,Edouard Laforgue,Samuel Bulteau,Véronique Thomas-Ollivier Australian and New Zealand Journal of Psychiatry, 2018, 52 (3), pp.291-293. ⟨10.1177/0004867417742520⟩ Article dans une revue hal-03158607v1
Efficacy of Intermittent Theta Burst Stimulation (iTBS) and 10-Hz High-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment-Resistant Unipolar Depression: Study Protocol for a Randomised Controlled Trial Samuel Bulteau,Véronique Sébille,Guillemette Fayet,Veronique Thomas-Ollivier,Thibault Deschampset al. Trials, 2017, 18 (1), pp.17. ⟨10.1186/s13063-016-1764-8⟩ Article dans une revue hal-03158125v1

Thèse (1)

Facteurs du mésusage des traitements psychotropes : des prescriptions non-conformes aux usages inappropriés Edouard-Jules Laforgue Médecine humaine et pathologie. Nantes Université, 2022. Français. ⟨NNT : 2022NANU1044⟩ Thèse tel-04282983v1